Full Text View
Tabular View
No Study Results Posted
Related Studies
Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease
This study is ongoing, but not recruiting participants.
Study NCT00528073   Information provided by Alfa Wassermann S.p.A.
First Received: September 10, 2007   Last Updated: April 20, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Crohn's Disease
Additional conditions recognized in this trial
Crohn Disease
Enteritis
Ileitis
More general conditions related to this trial
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Ileal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Interventions listed in this trial
Rifaximin-EIR
Additional drug interventions recognized in this trial
Rifaximin
More general drug interventions related to this trial
Anti-Infective Agents
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Alfa Wassermann S.p.A.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services